Intas Pharma appoints Sarang Pande as Vice President - Digital Manufacturing & Industry Automation

Published On 2025-04-17 07:00 GMT | Update On 2025-04-17 07:00 GMT

Ahmedabad: Intas Pharma has announced the appointment of Sarang Pande as Vice President - Digital Manufacturing & Industry Automation.

In a recent LinkedIn post, the pharmaceutical major welcomed Pande to the leadership team, stating, "We’re delighted to welcome Sarang Pande as Vice President – Digital Manufacturing & Industry Automation.

"With 17+ years of expertise in leading digital transformation initiatives across pharmaceutical manufacturing, Sarang brings a wealth of knowledge in program management, data governance, and process digitization. His strategic vision and experience will be instrumental in accelerating our digital journey and achieving our ambitious goals," the Company further stated.

"Excited to power the next leap of digital transformation at Intas, where innovation is not just embraced- it's engineered!" Sarang Pande said.

Read also: Intas Pharma appoints Parthiv Mehta as Vice President - Rest of Africa & International Fertility

Sarang is a professional with 19 years of diversified experience in Pharmaceutical sector. Prior to joining Intas, he served for over nine years at

Dr. Reddy's Labs in Hyderabad. His previous engagements include tenures at leading firms such as Piramal Enterprises, Sandoz, Cipla, Pfizer Global Supply.

He has expertise in business translation for implementation of Industry 4.0 solutions including various Advanced analytics based solutions, created an overall impact on various Business KPIs performance. He has strong pharmaceutical manufacturing domain knowledge.

Pande holds a Bachelor’s and Master’s degree in Chemical Engineering from Doctor Babasaheb Ambedkar Technological University. He further pursued PGPEX-VLM, Operations management from Indian Institute of Management, Calcutta.

Intas is a leading, vertically integrated global pharmaceutical formulation development, manufacturing, and marketing company. Intas has set up a network of subsidiaries, under the umbrella name of Accord Healthcare to operate in global markets. Over the years, Intas has grown both organically and via acquisition, expanding its product portfolio and operations year on year. It is currently present in more than 85 countries worldwide. Intas is currently investing in a higher barrier to entry developments such as Biosimilar and New Chemical Entities.

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Ruchika Sharma

Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751

Comments Policy

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Intas Pharma appoints Sarang Pande as Vice President - Digital Manufacturing & Industry Automation

Similar News

CDSCO Panel Nod To Phase I Clinical Trial of Anticancer Drug Bevacizumab by Jeevan Scientific

Orissa HC Seeks Govt Roadmap on Advanced Blood Testing Technology

AstraZeneca Faces NPPA Heat Over Symbicort Pricing, Slapped Rs 60 Crore Showcause Notice

Fixed Dose Combination of Metformin-Voglibose Now CDSCO Approved

Insufficient Efficacy, Safety Data: CDSCO Panel Rejects Zydus' Phase III CT Waiver Request for Voclosporin

Torrent Pharma Brand Misused in Online Investment Scam, Fake Portals Promising High Returns Busted

Alembic Pharma gets USFDA EIR for 2 API facilities in Panelav

Raid at quack clinic in Telangana, drugs illegally stocked for sale seized